Search Within

Genitourinary Oncology Service

Formats
  1. Journal Article (2795)
  2. Meeting Abstract (2524)
  3. Review (119)
  4. Book Section (83)
  5. Editorial (57)
  6. Correspondence (34)
  7. Conference Paper (29)
  8. Guidelines (25)
  9. Research Letter (18)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Solid Tumor Oncology Division (5692)
  2. Department of Medicine (5682)
  3. GSK Faculty (1658)
  4. Human Oncology and Pathogenesis Program (1157)
  5. Department of Pathology and Laboratory Medicine (1129)
  6. Surgery (1021)

More Groups

People
  1. Robert Motzer (1252)
  2. Howard Scher (1133)
  3. David Solit (785)
  4. Dean Bajorin (664)
  5. Michael Morris (587)
  6. Jonathan Rosenberg (525)

More People

Years
  1. 2025 (200)
  2. 2024 (294)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1713)
  2. Annals of Oncology (304)
  3. Clinical Cancer Research (283)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (123)

More Publications

Publishers
  1. American Society of Clinical Oncology (1780)
  2. American Association for Cancer Research (689)
  3. Oxford University Press (414)
  4. Elsevier Science, Inc. (396)
  5. Elsevier Inc. (380)
  6. Nature Publishing Group (302)

More Publishers

Results (5692)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Total androgen-receptor gene expression inhibitor therapy (TARGET): A phase II trial of neoadjuvant SAHA (S) followed prostatectomy for patients (pts) with high-risk prostate cancer (pc)
    Meeting Abstract

    Slovin, S. F.; Fine, S.; Nelson, P.; Steinbrecher, J.; Eastham, J.; Coleman, J.; Touijer, K. A.; Carver, B. S.; Laudone, V.; Scher, H. I.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Docetaxel (D) plus high-dose calcitriol versus D plus prednisone (P) for patients (Pts) with progressive castration-resistant prostate cancer (CRPC): Results from the phase III ASCENT2 trial
    Meeting Abstract

    Scher, H. I.; Chi, K. N.; De Wit, R.; Berry, W. R.; Albers, P.; Henick, B.; Venner, P.; Heidenreich, A.; Chu, L.; Heller, G.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Anti-insulin-like growth factor-1 receptor (IGF-IR) monoclonal antibody cixutumumab plus mammalian target of rapamycin (mTOR) inhibitor temsirolimus in metastatic castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Rathkopf, D. E.; Danila, D. C.; Chudow, J. J.; Morris, M. J.; Slovin, S. F.; Fine, S.; Fox, J. J.; Larson, S. M.; Rosen, N.; Scher, H. I.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Efficacy and safety of everolimus in elderly patients (pts) with metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Osanto, S.; Hutson, T. E.; Calvo, E.; Escudier, B. J.; Oudard, S.; Porta, C.; Bracarda, S.; Grunwald, V.; Ravaud, A.; Motzer, R. J.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • TWiST analysis to estimate overall benefit for metastatic renal cell carcinoma (mRCC) patients (pts) treated in a phase III trial of sunitinib versus interferon-alfa (IFN-alpha)
    Meeting Abstract

    Patil, S.; Figlin, R. A.; Hutson, T. E.; Michaelson, D.; Negrier, S.; Kim, S. T.; Huang, X.; Motzer, R. J.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • HE3235, a synthetic adrenal hormone disease-modifying agent, in castrate resistant prostate cancer (CRPC): Results of phase I/II clinical trial
    Meeting Abstract

    Montgomery, R. B.; Morris, M. J.; Ryan, C. J.; Stickney, D. R.; Frincke, J. M.; Reading, C. L.; Sarantopoulos, J.; Scher, H. I.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Fluorodeoxyglycose (FDG) PET as an outcome measure for metastatic prostate cancer
    Meeting Abstract

    Morris, M. J.; Fox, J. J.; Dennis, E. R.; Tse, K.; Flatts, E.; Heller, G.; Jia, X.; Schoder, H.; Larson, S. M.; Scher, H. I.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Long-term responders to sunitinib therapy for metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Molina, A. M.; Jia, X.; Ginsberg, M. S.; Velasco, S.; Feldman, D. R.; Patil, S.; Motzer, R. J.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium
    Meeting Abstract

    Milowsky, M. I.; Trout, A.; Regazzi, A. M.; Garcia-Grossman, I.; Flaherty, A.; Tickoo, S.; Al-Ahmadie, H.; Bajorin, D. F.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • A gene expression signature associated with sensitivity to the multikinase inhibitor dasatinib: Implications for development of a noninvasive biomarker for personalized therapy based on circulating tumor cell analysis
    Meeting Abstract

    Mitsiades, N.; Antipin, Y.; Reva, B.; Schultz, N.; Danila, D. C.; Sung, C. C.; Anand, A.; Sander, C.; Scher, H. I.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save